Charles River Laboratories International, Inc. (CRL)

215.37
2.60 1.20
NYSE
Prev Close 217.97
Open 219.18
Day Low/High 213.18 / 220.00
52 Wk Low/High 95.58 / 220.01
Volume 78.09K
Exchange NYSE
Shares Outstanding 49.49B
Market Cap 10.09B
P/E Ratio 40.95
Div & Yield N.A. (N.A)

Latest News

Healthy Upside Potential In Medical Devices and Services Stocks

Healthy Upside Potential In Medical Devices and Services Stocks

Some of the best opportunities are in lesser-known niche markets such as medical devices and services.

Charles River Labs Won't See Its Narrow Trading Range Last Forever

Charles River Labs Won't See Its Narrow Trading Range Last Forever

The contract research company's shares will not stay in a tight trading range indefinitely, so would-be buyers should be prepared to act.

Don't Jump Into Charles River Labs Just Yet

Don't Jump Into Charles River Labs Just Yet

CRL could weaken further in upcoming weeks for a better buying opportunity.

Charles River Laboratories Could Suffer a Pullback Before Moving Still Higher

Charles River Laboratories Could Suffer a Pullback Before Moving Still Higher

CRL looks strong and probably capable of further gains but in the short-run we could see a pullback.

Trade Wars: Winners & Losers for Investors

Trade Wars: Winners & Losers for Investors

Argus Research details 24 stocks likely to be impacted, one way or the other, by trade wars and tariffs.

Charles River upgraded at Goldman

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

Charles River upgraded at Wells

Charles River, Rambus and Verint Shares Ready to Race Higher

Charles River, Rambus and Verint Shares Ready to Race Higher

It’s not easy for value investors to gain exposure to the growth-fueled and often-pricey biotech sector.

Day Ahead: FOMC Aftermath; Earnings Continue

Day Ahead: FOMC Aftermath; Earnings Continue

There is building consensus around a September rate hike.

Charles River downgraded at Barclays

Charles River downgraded at Wells

The Market Lacks Liquidity

Brokers are hesitant to take risks due to regulations.

Rules of the Game: Healthcare Hangs Tough

Hospitals, biotechs and drug makers continue to hold their own.

Charles River initiated Neutral at UBS

Big Pharma Has Lost Its Way

Big Pharma Has Lost Its Way

Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.

Charles River upgraded at JP Morgan